Patent · US Active

LTBP2 as a biomarker and diagnostic target

US8088584B2 · kind B2 · utility

2Cited by

0References

4Claims

0Family size

Assignee

Bayer Schering Pharma AG · DE

Inventors

Stefan Golz · Wetter (Ruhr), DE
Holger Summer · Wuppertal, DE
Andreas Geerts · Wuppertal, DE
Ulf Bruggemeier · Leichlingen, DE
Barbara Albrecht-Küpper · Uerdingen, DE
Martina Klein · Mülheim an der Ruhr, DE
Sonja Steppan · Neu-Isenburg, DE
Peter Ellinghaus · Melle, DE
Donatella D'Urso · Mülheim an der Ruhr, DE
Michael Seewald · Berlin, DE
Hendrik Milting · Bad Oeynhausen, DE

Key dates

Filing date	Oct 2, 2007
Grant date	Jan 3, 2012
Priority date	—
Expiry date	Oct 2, 2027

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S530/841
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.